CN1799544A - Compound bergenin pills and its preparation method - Google Patents

Compound bergenin pills and its preparation method Download PDF

Info

Publication number
CN1799544A
CN1799544A CN 200410079652 CN200410079652A CN1799544A CN 1799544 A CN1799544 A CN 1799544A CN 200410079652 CN200410079652 CN 200410079652 CN 200410079652 A CN200410079652 A CN 200410079652A CN 1799544 A CN1799544 A CN 1799544A
Authority
CN
China
Prior art keywords
preparation
bergeninum
drop pill
pills
compound bergenin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200410079652
Other languages
Chinese (zh)
Other versions
CN100341507C (en
Inventor
陈庆党
何国民
宾燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yunnan Baiyao Group Co Ltd
Original Assignee
Yunnan Baiyao Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yunnan Baiyao Group Co Ltd filed Critical Yunnan Baiyao Group Co Ltd
Priority to CNB2004100796525A priority Critical patent/CN100341507C/en
Publication of CN1799544A publication Critical patent/CN1799544A/en
Application granted granted Critical
Publication of CN100341507C publication Critical patent/CN100341507C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a novel medicinal dosage for treating chronic bronchitis and common cold, and its preparing process, which comprises medicinal active constituents and medicinal auxiliary materials, wherein the active components of the medicament include Bergenin 8-42 wt% and chlorpheniramine 0.001-0.01 wt%, and balancing medicinal auxiliary materials.

Description

Compound bergenin pills and preparation method
Technical field
The present invention relates to this medicine of a kind of medicine for the treatment of chronic bronchitis and cold cough, especially novel form and preparation method thereof.
Background technology
Bergeninum is a kind of extract of plant amedica, has the effect of relieving cough and expelling phlegm, can be used for treating chronic bronchitis.Curative effect can be affirmed, but onset time is slower.Main cause is that Bergeninum is a poorly water soluble drugs, and it is slow to make tablet stripping in human body with general disintegrating process, and bioavailability is low, thereby influences the performance of optimal efficacy.Therefore the bioavailability that how to improve behind the Bergeninum preparation oral is an important difficult problem in this field, is not resolved as yet so far.
Summary of the invention
The objective of the invention is to overcome the deficiencies in the prior art, a kind of oral back dissolution height is provided, bioavailability is compound bergenin pills preferably.
Another object of the present invention provides the preparation method of this compound bergenin pills.
Compound bergenin pills of the present invention is made up of active constituents of medicine and pharmaceutic adjuvant, described active constituents of medicine is Bergeninum and chlorphenamine, and its percentage by weight is: Bergeninum 8-42%, chlorphenamine 0.001-0.01%, surplus are pharmaceutic adjuvant.
Above-mentioned Bergeninum claims bergenin again, is the active ingredient of extracting from saxifragaceae plant Rhizoma Seu Herba Bergeniae BergrniaPurpurascens (Hook.f.et.Thoms.) Engl. or Yunnan Rhizoma Seu Herba Bergeniae Bergrnia Purpurascens (Hook.f.et.Thoms.) Engl.Vardelavayi (Franch) Engl.etirm rhizome.Bergeninum and chlorphenamine are prior art.
Above-mentioned pharmaceutic adjuvant is Polyethylene Glycol (PEG) 6000, Polyethylene Glycol (PEG) 4000, lecithin (PC).Can be wherein one or more.
The preparation method of compound bergenin pills of the present invention is divided into two kinds of fusion method and solvent methods.
The preparation method of compound bergenin pills of the present invention is made up of following steps:
One, gets the abundant mixing of Bergeninum, chlorphenamine and pharmaceutic adjuvant, put in 60 ℃-95 ℃ the water-bath fully thermosol;
Two, pour in the drop pill organizational security temperature charging apparatus, 60 ℃-90 ℃ of holding temperatures splash in the condensed fluid with per minute 40-90,5 ℃-16 ℃ of condensate temperatures;
Three, drip off the back and with filter paper the condensing agent of drop pill surface attachment inhaled and gone, put in the baking oven in 30 ℃-45 ℃ dry 12-24 hour, get product after the packing.
Above-mentioned condensed fluid is liquid Paraffin, vegetable oil, methyl-silicone oil etc.
The preparation method of compound bergenin pills of the present invention is made up of following steps:
One, gets Bergeninum and chlorphenamine, add in 60 ℃ of-80 ℃ of ethanol and dissolve, treat that medicine is all molten intact;
Two, get it filled and pour in the above-mentioned solution with adjuvant, the limit edged is stirred to dissolving fully, reclaims ethanol to there not being the alcohol flavor;
Three, pour in the drop pill organizational security temperature charging apparatus, 60 ℃-90 ℃ of holding temperatures splash in the condensed fluid with per minute 40-90,5 ℃-16 ℃ of condensate temperatures;
Four, drip off the back and with filter paper the condensing agent of drop pill surface attachment inhaled and gone, put in the baking oven in 30 ℃-45 ℃ dry 12-24 hour, get product after the packing.
Above-mentioned concentration of alcohol is 75%-95%, and its addition is Bergeninum and chlorphenamine 10-30 a times.Above-mentioned condensed fluid is liquid Paraffin, vegetable oil, methyl-silicone oil etc.
It is very close with the dispersity relation of medicine that solution of the present invention is based on the release-absorption of insoluble drug in the pharmaceutical preparation, very big to its medicine absorption in vivo influence, with the dispersity powder that general breaking method makes, often bioavailability is lower in vivo.This just need reach the purpose that improves bioavailability by changing the dispersity that methods such as dosage form, composition and technical process change medicine.
The present invention is exactly by changing dosage form, add macromolecule carrier (substrate), change preparation process, utilize solid dispersion technology, improve the dissolution of Bergeninum, improving its bioavailability in vivo.The dispersion technology of solid drugs, particularly insoluble drug when solid dispersion technology is meant the preparation preparation.Solid dispersion is meant the medicine high degree of dispersion in carrier, forms a kind of disperse system that exists with solid form.Insoluble drug is dispersed in the solid dispersion that obtains medicine one carrier in the carrier of a kind of no physiologically active (water soluble polymer substrate) by certain method, medicine is superfine colloid and ultrafine dust in solid dispersion, even molecularity exists.
Study of pharmacy and part pharmacological research:
1, the present invention and compound bergenin pills dissolution contrast test
Compound bergenin pills (Kunming biological preparation factory, lot number: 20020201) dissolution (%) measurement result:
Time Measure number of times Date processing
T (branch) 1 2 3 4 5 X SD
3 39.6 43.2 28.8 32.4 18 32.4 9.8590
5 46.8 72 54 57.6 32.4 52.56 14.5343
8 61.2 57.6 61.2 61.2 46.8 57.6 7.2000
10 60.15 75 46.8 72 46.8 60.15 15.4638
15 64.2 79.2 68.4 68.4 61.8 68.28 6.8200
20 72 82.8 79.2 82.8 68.4 77.04 6.5397
30 87.3 86.4 108 86.4 68.4 87.3 16.2000
45 82.8 86.4 79.2 86.4 75.6 82.08 4.6938
60 72 90 72 97.2 67.5 79.74 13.0360
Dissolution of the present invention (%) measurement result:
Time Measure number of times Date processing
T (branch) 1 2 3 4 5 X SD
3 18 32.4 25.2 10.2 28.8 28.8 8.8832
5 43.2 46.8 57.6 39.6 57.6 48.96 8.2878
8 72 79.2 86.4 64.8 82.8 77.04 8.6699
10 104.4 93.6 86.4 86.4 90 92.16 7.4651
15 93.6 97.2 100.8 86.4 97.2 95.04 5.4597
20 108 101.6 108 93.6 97.2 101.68 6.4274
30 104.4 82.8 97.2 90 100.8 95.04 8.6699
45 111.6 82.8 108 104.4 100.8 101.52 11.2121
60 90 109.6 100.8 100.8 97.2 99.68 7.0846
Above compound bergenin pills, five dissolutions of compound bergenin pills (%) meansigma methods are carried out date processing with weighted least-squares method, calculate T50, the Td of compound bergenin pills and compound bergenin pills, the dissolution time of T70, T80 respectively:
The result shows that dissolution of the present invention is better and complete than compound bergenin pills.
2, the present invention and compound bergenin pills bioavailability contrast test
Method according to the pharmacopeia regulation, carry out the present invention and compound bergenin pills (Kunming biological preparation factory with rat, lot number: 20020201) Isodose contrast test, as testing index, the result shows that bioavailability of the present invention is than compound bergenin pills height with Bergeninum (the Chinese biological goods are identified the 1532-200202 of institute).
3, the present invention and compound bergenin pills (Kunming biological preparation factory, lot number 20020201) cough-relieving test
Method: get white mice, body weight 18-22g is divided into blank group, positive administration group, the basic, normal, high dosage group of the present invention, compound bergenin pills group at random.Behind the gastric infusion 1 hour, place strong aqua ammonia to draw mice and cough in the device, make mice quantitatively regularly suck strong aqua ammonia and cause and cough, observe mouse cough number of times in the incubation period and 3 minutes that begins to occur coughing, the result adopts the t check to handle relatively:
Group Number of animals (only) Dosage (mg/Kg) The cough number of times Cough latent period (second)
The blank group 20 31.6±15.86 39.2±18.77
Carbetapentane citrate tablet 10 20 15.4±7.38 66.95±32.5
Compound bergenin pills 10 80.4 20.2±8.84 55.1±21.36
The drop pill low dosage 20 40.2 17.2±12.33 54±26.26
Dosage in the drop pill 20 80.4 15.70±11.6 54.15±21.48
The drop pill high dose 10 160.8 13.50±5.78 64.8±25.36
Show that antitussive action of the present invention is better than compound bergenin pills.
The specific embodiment
Embodiment 1: get 30 parts of Bergeninums, and 0.48 part of chlorphenamine, 269.52 parts of PEG6000 promptly get every drop pill finished product that contains the plain 3mg of Rhizoma Seu Herba Bergeniae by above-mentioned fusion legal system.
Embodiment 2: get 45 parts of Bergeninums, and 0.72 part of chlorphenamine, 254.28 parts of PEG4000 promptly get every drop pill finished product that contains the plain 4.5mg of Rhizoma Seu Herba Bergeniae by above-mentioned fusion legal system.
Embodiment 3: get 60 parts of Bergeninums, and 0.96 part of chlorphenamine, 239.04 parts of PEG6000 promptly get every drop pill finished product that contains the plain 6mg of Rhizoma Seu Herba Bergeniae by above-mentioned fusion legal system.
Embodiment 4: get 75 parts of Bergeninums, and 1.2 parts of chlorphenamines, 223.8 parts of PEG4000 promptly get every drop pill finished product that contains the plain 7.5mg of Rhizoma Seu Herba Bergeniae by above-mentioned fusion legal system.
Embodiment 5: get 90 parts of Bergeninums, and 1.44 parts of chlorphenamines, 208.56 parts of PEG6000 promptly get every drop pill finished product that contains the plain 9mg of Rhizoma Seu Herba Bergeniae by above-mentioned fusion legal system.
Embodiment 6: get 105 parts of Bergeninums, and 1.68 parts of chlorphenamines, 193.32 parts of PEG4000 promptly get every drop pill finished product that contains the plain 10.5mg of Rhizoma Seu Herba Bergeniae by above-mentioned solvent legal system.
Embodiment 7: get 120 parts of Bergeninums, and 1.92 parts of chlorphenamines, 178.08 parts of PEG6000 promptly get every drop pill finished product that contains the plain 12mg of Rhizoma Seu Herba Bergeniae by above-mentioned solvent legal system.
Embodiment 8: get 90 parts of Bergeninums, and 1.44 parts of chlorphenamines, 104.28 parts of PEG6000,104.28 parts of PEG4000 promptly get every drop pill finished product that contains the plain 9mg of Rhizoma Seu Herba Bergeniae by above-mentioned solvent legal system.
Embodiment 9: get 105 parts of Bergeninums, and 1.68 parts of chlorphenamines, 32.22 parts of PEG6000,161.10 parts of PEG4000 promptly get every drop pill finished product that contains the plain 10.5mg of Rhizoma Seu Herba Bergeniae by above-mentioned solvent legal system.
Embodiment 10: get 120 parts of Bergeninums, and 1.92 parts of chlorphenamines, 4,000 176.18 parts of PEG, 1.9 parts of PC promptly get every drop pill finished product that contains the plain 12mg of Rhizoma Seu Herba Bergeniae by above-mentioned solvent legal system.
Content of the present invention is not limited to embodiment.

Claims (6)

1, a kind of compound bergenin pills, it is characterized in that forming by active constituents of medicine and pharmaceutic adjuvant, described active constituents of medicine is Bergeninum and chlorphenamine, and its percentage by weight is: Bergeninum 8-42%, chlorphenamine 0.001-0.01%, surplus are pharmaceutic adjuvant.
2,, it is characterized in that described pharmaceutic adjuvant is polyethylene glycol 6000, Macrogol 4000, lecithin according to the described compound bergenin pills of claim 1.
3,, it is characterized in that forming by following steps according to the preparation method of the described compound bergenin pills of claim 1:
One, gets the abundant mixing of Bergeninum, chlorphenamine and pharmaceutic adjuvant, put in 60 ℃-95 ℃ the water-bath fully thermosol;
Two, pour in the drop pill organizational security temperature charging apparatus, 60 ℃-90 ℃ of holding temperatures splash in the condensed fluid with per minute 40-90,5 ℃-16 ℃ of condensate temperatures;
Three, drip off the back and with filter paper the condensing agent of drop pill surface attachment inhaled and gone, put in the baking oven in 30 ℃-45 ℃ dry 12-24 hour, get product after the packing.
4,, it is characterized in that described condensed fluid is liquid Paraffin, vegetable oil, methyl-silicone oil according to the preparation method of the described compound bergenin pills of claim 3.
5,, it is characterized in that forming by following steps according to the preparation method of the described compound bergenin pills of claim 1:
One, gets Bergeninum and chlorphenamine, add in 60 ℃ of-80 ℃ of ethanol and dissolve, treat that medicine is all molten intact;
Two, get it filled and pour in the above-mentioned solution with adjuvant, the limit edged is stirred to dissolving fully, reclaims ethanol to there not being the alcohol flavor;
Three, pour in the drop pill organizational security temperature charging apparatus, 60 ℃-90 ℃ of holding temperatures splash in the condensed fluid with per minute 40-90,5 ℃-16 ℃ of condensate temperatures;
Four, drip off the back and with filter paper the condensing agent of drop pill surface attachment inhaled and gone, put in the baking oven in 30 ℃-45 ℃ dry 12-24 hour, get product after the packing.
6,, it is characterized in that described condensed fluid is liquid Paraffin, vegetable oil, methyl-silicone oil according to the preparation method of the described compound bergenin pills of claim 5.
CNB2004100796525A 2004-12-31 2004-12-31 Compound bergenin pills and its preparation method Expired - Fee Related CN100341507C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2004100796525A CN100341507C (en) 2004-12-31 2004-12-31 Compound bergenin pills and its preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2004100796525A CN100341507C (en) 2004-12-31 2004-12-31 Compound bergenin pills and its preparation method

Publications (2)

Publication Number Publication Date
CN1799544A true CN1799544A (en) 2006-07-12
CN100341507C CN100341507C (en) 2007-10-10

Family

ID=36809904

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100796525A Expired - Fee Related CN100341507C (en) 2004-12-31 2004-12-31 Compound bergenin pills and its preparation method

Country Status (1)

Country Link
CN (1) CN100341507C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105832752A (en) * 2016-04-08 2016-08-10 王金霞 Pharmaceutical composition for clinical nursing of upper respiratory infection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06100640A (en) * 1992-09-22 1994-04-12 Kansai Paint Co Ltd Actinic-radiation-during colored coating composition for vacuum-formable film, vacuum-formable film and vacuum-formed article

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105832752A (en) * 2016-04-08 2016-08-10 王金霞 Pharmaceutical composition for clinical nursing of upper respiratory infection

Also Published As

Publication number Publication date
CN100341507C (en) 2007-10-10

Similar Documents

Publication Publication Date Title
Lu et al. Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release
CN102961368B (en) Curcumin nanosuspension and preparation method thereof
CN106265641A (en) A kind of pharmaceutical composition containing vildagliptin and metformin and preparation method thereof
CN1762401A (en) Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof
CN103356491A (en) Preparation method of syringopicroside (SYR) poly(lactide-co-glycolide) (PLGA) nanoparticles
US20180177777A1 (en) Formulations for mitigating opioid overdose and methods of making and using the same
CN100341507C (en) Compound bergenin pills and its preparation method
CN106727362A (en) A kind of Triptorelin microballoon and preparation method and application
CN1698591A (en) Ginger phenols extract microcapsule and preparation method thereof
CN107362142A (en) A kind of fulvestrant lipidosome injection and preparation method thereof
CN1250216C (en) Medication for treating acute hepatitis and chronic hepatitis and preparation technique
CN1259099C (en) Prepared traditional Chinese drug Liangfu drop pills for treating epigastric pain
CN1299667C (en) Nano Chinese medicine threewingnut/Tripterygium prepn and its prepn process
Yadav et al. Encapsulation of repaglinide into eudragit RS microspheres and modulation of their release characteristics by use of surfactants
CN113164395A (en) Long-acting naltrexone microparticle composition for injection
CN104510716A (en) Excipient-containing lyophilized paclitaxel powder preparation and preparation method thereof
CN1872179A (en) Microspheres in use for injection of Chinese traditional medicine of containing astragalus root, and preparation method
CN107669720A (en) Compound ginseng ganoderma spove powder micro-capsule and preparation method thereof
CN1883601A (en) Chinese medicinal capsule for treating inflammation and method for preparing same
CN1939323A (en) Bean-curd fruit aglycone preparation and its making method
CN104510715A (en) Excipient-containing lyophilized paclitaxel powder preparation and preparation method thereof
CN103976957A (en) 20 (S)-protopanaxadiol microsphere and preparation method and application thereof
CN1872156A (en) Microspheres in use for injection of anginin, and prepartion method
CN104510713A (en) Excipient-containing lyophilized paclitaxel powder preparation and preparation method thereof
CN1241556C (en) Emodin injection preparation and its preparation method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071010

Termination date: 20201231